Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Demannose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MPI | P34949 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demannose SCHEMBL30973585 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL3397670 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL361547 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL31755099 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL23721809 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL285569 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL25380809 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL25381696 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Galactose SCHEMBL361095 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A | |
| Demannose SCHEMBL30572907 | 1.00 | LMNA (0.48) | LMNAL3MBTL1TDP1MPIPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4500182-A1 | PROGNOSTIC BIOMARKERS | The University of Liverpool (GB) | 2025-02-05 | — | — | EP | claimed |
| CN-117535277-A | Immobilized enzyme and method for preparing D-tagatose by using immobilized enzyme | 东台市浩瑞生物科技有限公司 | 2024-02-09 | — | — | CN | claimed |
| CN-116999376-A | Active substance combinations for cosmetic preparations | 拉普雷集团股份有限公司 | 2023-11-07 | — | — | CN | claimed |
| CN-116999377-A | Use of caviar extract | 拉普雷集团股份有限公司 | 2023-11-07 | — | — | CN | claimed |
| WO-2023180753-A1 | PROGNOSTIC BIOMARKERS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-09-28 | — | — | WO | claimed |
| CN-105164270-B | The method that rebandioside A is prepared by stevioside | CJ第一制糖株式会社 | 2019-07-09 | — | — | CN | claimed |
| CN-109929791-A | It is a kind of accumulate Glucosamine recombination bacillus coli and its application | 扬州日兴生物科技股份有限公司 | 2019-06-25 | — | — | CN | claimed |
| CN-107739728-A | A kind of recombination bacillus coli of efficiently production Glucosamine and its application | 江南大学 | 2018-02-27 | — | — | CN | claimed |
| CN-106148260-A | The recombined bacillus subtilis of high yield acetylglucosamine and construction method thereof | 江南大学 | 2016-11-23 | — | — | CN | claimed |
| EP-1311847-A2 | QUANTITATIVE ANALYSIS OF HEXOSE-MONOPHOSPHATES FROM BIOLOGICAL SAMPLES | Statens Serum Institut (DK) | 2003-05-21 | — | — | EP | claimed |
| WO-2002010740-A2 | QUANTITATIVE ANALYSIS OF HEXOSE-MONOPHOSPHATES FROM BIOLOGICAL SAMPLES | STATENS SERUM INSTITUT (DK) | 2002-02-07 | — | — | WO | claimed |
| US-20250281465-A1 | MOLECULES THAT ENHANCE EXTRACELLULAR VESICLE RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-09-11 | — | — | US | disclosed |
| US-20250243525-A1 | BIOCATALYTIC MANUFACTURE OF SUGAR NUCLEOTIDES | ZYMTRONIX CATALYTIC SYSTEMS, INC. (US) | 2025-07-31 | — | — | US | disclosed |
| CN-119768515-A | Biocatalytic manufacture of sugar nucleotides | 齐姆特罗尼克斯催化系统股份有限公司 | 2025-04-04 | — | — | CN | disclosed |
| EP-4514352-A1 | MOLECULES THAT ENHANCE EXTRACELLULAR VESICLE RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-1150709-A2 | ANTI-MICROBIAL AGENTS, DIAGNOSTIC REAGENTS, AND VACCINES BASED ON APICOMPLEXAN PARASITE COMPONENTS | Mcleod, Rima W. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000066154-A2 | ANTI-MICROBIAL AGENTS, DIAGNOSTIC REAGENTS, AND VACCINES BASED ON UNIQUE APICOMPLEXAN PARASITE COMPONENTS | ARCH DEVELOPMENT CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-0918868-A2 | ANTIMICROBIAL AGENTS, DIAGNOSTIC REAGENTS, AND VACCINES BASED ON UNIQUE APICOMPLEXAN PARASITE COMPONENTS | ARCH DEVELOPMENT CORPORATION (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1998003661-A9 | ANTIMICROBIAL AGENTS, DIAGNOSTIC REAGENTS, AND VACCINES BASED ON UNIQUE APICOMPLEXAN PARASITE COMPONENTS | — | 1998-05-28 | — | — | WO | disclosed |
| WO-1998003661-A2 | ANTIMICROBIAL AGENTS, DIAGNOSTIC REAGENTS, AND VACCINES BASED ON UNIQUE APICOMPLEXAN PARASITE COMPONENTS | ARCH DEVELOPMENT CORPORATION (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281465-A1 | MOLECULES THAT ENHANCE EXTRACELLULAR VESICLE RELEASE | ORAI1, CHERP, CASR | LMNA 2270/4885L3MBTL1 4468/4885TDP1 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.